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Purpose: The characterization of the human trabecular meshwork (TM) proteome is a valuable step toward understanding
its role under normal and glaucomatous conditions. This study uses proteomic techniques to investigate the set of proteins
expressed in normal human TM and to identify those differentially expressed in response to dexamethasone (DEX)
treatment of TM cells (TMCs) in vitro.
Methods: TM tissue (TMT) was isolated from human donor eyes and pooled. Immortalized human TMCs were cultured
with or without DEX. Protein extracts from each were separated by two-dimensional electrophoresis (2-DE). Protein spots
in TMT gel were excised, destained, and subjected to in-gel tryptic digestion and identification with matrix-assisted laser
desorption/ionization  time-of-flight  mass  spectrometry  (MALDI-TOF-MS).  To  determine  those  proteins  whose
expression  patterns  were  affected  by  glucocorticoids,  TMCs  were  treated  with  DEX  and  assayed  by  3-(4,5-
dimethylthiazol-2-yl)-2,5-  diphenyltetrazolium  bromide  (MTT)  dye  and  2-DE.  A  differentially  expressed  protein,
RhoGDI, was validated by both western blotting and immunocytological staining.
Results: The comprehensive protein set included more than 850 protein spots from both the TMT and TMCs, as visualized
on 2-DE gel. Two-hundred-and-thirty-five spots were successfully identified in the TMT gel. The functional categories
of the identified proteins were mainly comprised of metabolic process, cell adhesion, anti-apoptosis, cell motility,
carbohydrate metabolic process, signal transduction, and regulation of transcription. During three days of DEX treatment,
TMCs’ proliferation was inhibited in a time- and dose-dependent manner, as evidenced by MTT assay. In the 48 h cultured
cell group, RhoGDI expression was reduced, as detected by 2-DE, western blotting, and immunocytological staining. In
contrast, the expression of RhoA, a target of RhoGDI, increased in response to DEX treatment.
Conclusions: Using the classic proteomic workflow, the main protein complement of normal human TMT was detected,
identified, and categorized. The DEX inhibition of RhoGDI expression in TMCs was evidenced.
Primary open-angle glaucoma (POAG) is one of the most
common eye diseases causing progressive asymptomatic loss
of bilateral vision and visual field resulting in blindness. Since
aqueous  humor  drains  mainly  through  the  trabecular
meshwork  (TM)  into  Schlemm’s  canal  and  the  episcleral
veins, the increased intraocular pressure (IOP) is due to an
increased resistance to aqueous humor outflow in the TM, a
complex  of  endothelium-like  cells  surrounded  by  the
extracellular matrix (ECM) [1-4]. The common eye disease,
glaucoma,  originates  from  malfunction  of  the  TM  tissue
(TMT), and is believed to be responsible for the development
of  POAG.  On  the  other  hand,  glucocorticoid-induced
glaucoma is similar to that of POAG, both in its clinical
presentation and pathological TM changes, including effects
on  the  (ECM),  cytoskeleton,  gene  expression,  and  cell
function [2,5-9]. Therefore, treating cells and animals with
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glucocorticoids has resulted in the creation of effective in vitro
and in vivo models for glaucoma research.
TMT proteins involved in maintaining physiologic and
pathological status have been extensively studied. Specific
genes and their products (e.g., trabecular meshwork-inducible
glucocorticoid response protein/myocilin [10-13], fibronectin
[14], optineurin [15], procollagen C-proteinase enhancer 1
(PCOLCE1) [16], cytochrome P450 1B1 [17]) found in TM
have been shown to play roles in glaucoma pathogenesis.
Another protein family that has been widely studied in TM
cells (TMCs) includes the Rho GTPase members, such as
RhoA and Rac [4,18-20]. Rho GTPases function in regulating
actin cytoskeletal organization, and cell adhesive interactions,
as well as influencing cell polarity, morphogenesis, migration,
vesicle trafficking, cell cycle progression, and transcriptional
activity  [4,21].  In  addition,  Rho  GTPase  has  been
demonstrated to influence aqueous humor outflow in TM by
regulating  the  actomyosin  assembly,  cell  adhesive
interactions, and expression of ECM proteins and cytokines
in  TMCs  [4,22-25].  The  Rho  GTPases  act  as  molecular
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213switches  by  cycling  between  active  guanosine-5’-
triphosphate  (GTP)-bound  and  inactive  guanosine-5’-
diphosphate  (GDP)-bound  forms.  Rho  GDP  dissociation
inhibitor (RhoGDI) negatively regulates Rho GTPase activity
by  inhibiting  GDP  dissociation  and  promoting  GTP
hydrolysis  [26,27].  To  our  knowledge,  the  differential
expression  status  of  RhoGDI  in  TMCs  has  yet  to  be
investigated.
Investigations  into  the  molecular  mechanism(s)
mediating  pathological  changes  of  TM  are  currently
underway using genomic techniques [13,28-30]. In addition,
proteome  analysis  has  been  used  to  study  the  protein
expression in TM from normal and glaucomatous eyes. Using
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE),  liquid  chromatography  electrospray  tandem
mass  spectrometry  (LC/MS/MS)  and  other  techniques,
Bhattacharya and his colleagues found that cochlin deposits
were associated with glaucomatous TM. Their studies also
revealed protein expression profiles altered between normal
and glaucoma TMT, wherein 52 out of 368 identified proteins
were detected exlusively in glaucomatous TM [31]. Using
proteomic  analysis  of  dexamethasone  (DEX)-treated  rats,
Shinzato et al. [32] reported that 14 proteins were up- or
downregulated  consistently  in  TM.  Of  these  14,  two
crystallins  (βA3  and  αA)  were  upregulated,  and  the  C-
propeptides of type I collagen were downregulated by more
than twofold. Although proteomic technologies have high
throughput  and  are  sensitive,  the  comprehensive
characterization of the human TM proteome, especially in
glaucoma patients, remains a challenge, because of the limited
availability of intact tissue.
Instead of using human TMT, previous proteomic studies
used TMC lines under varying culture treatments [29,33].
Steely et al. [33] used two-dimensional electrophoresis (2-
DE)  to  separate  proteins  in  a  transformed  TMC  strain
(GTM3); 87 primary proteins and 93 variants of these proteins
were identified by LC/MS/MS.
To investigate the protein expression profile of human
TM and to better understand the mechanisms causing elevated
IOP resulting from impaired aqueous humor circulation, we
performed 2-DE of TM from normal donors and from a TMC
line.  Gel  patterns  corresponding  to  the  global  protein
expression in normal human TM and the cultured TMC line
were  obtained.  Matrix-assisted  laser  desorption/ionization
time-of-flight  mass  spectrometry  (MALDI-TOF-MS)  and
bioinformatics  analysis  was  used  to  make  the  initial  step
toward  documenting  the  proteome  of  human  TMT;  235
protein spots on a 2-DE gel of TMT were identified and
categorized.  Furthermore,  by  analyzing  the  gel  pattern  of
DEX-treated TMCs and completing immunoassays, we found
that RhoGDI responded to the presence of DEX.
METHODS
Tissue procurement: Human eyes from 30 normal donors
(aged 20–35 years old) were obtained through the Guangdong
Province Eye Bank, China and used in this study. Within 12
h  after  death,  TMT  was  dissected  in  a  ring  shape.  The
possibility of contamination by small amounts of sclera was
noted, in accordance with the report by Bhattacharya et al.
[31,34]. Harvested TM samples were collected in tubes and
stored at −80 °C until use.
Cell culture: An immortal human trabecular meshwork cell
line  [35]  was  cultured  in  Dulbecco’s  modified  Eagle’s
medium and F12 (DMEM/F12) containing 15% newborn calf
serum.  TMCs  were  treated  with  different  levels  of  DEX
(10−5, 10−6, and 10−7 M) added to the medium for one- to three-
day durations. Since we hoped to find the early expressed
proteins responding to DEX treatment, we used a short-term
(i.e. within 3 days) cell culture, as previously reported [36,
37]. Meanwhile, besides the 10−7 M DEX used in most studies
[9,37,38], we also used 10−6 and 10−5 M DEX to see the more
obvious effects on TMCs. At various time points, cell cultures
were terminated for further analyses. The cellular changes
were  measured  by  phase-contrast  microscopy  and  3-(4,5-
dimethylthiazol-2-yl)-2,5-  diphenyltetrazolium  bromide
(MTT) assay (described below). Soluble proteins extracted
from the TMCs were used for subsequent 2-DE and western
blot analyses.
Cell viability assays: The proliferation rate of TMCs was
measured using an MTT assay [39]. Each group of TMCs was
trypsinized and seeded in 96-well plates with an initial density
of 5×103 cells per well. Subsequently, cells were cultured in
medium with various concentrations of DEX for 1, 2, or 3 d.
Upon color development, the absorbance of each sample was
measured using a multiwell scanning spectrophotometer. The
absorbance of each experiment was analyzed in five wells,
and three independent experiments were performed. Statistic
analysis  (Student’s  t-test)  was  conducted  to  compare  the
differences between DEX-treated and -untreated cells at each
time point.
Immunohistochemical assay: TMCs were cultured on a glass
coverslip in 12-well chamber dishes, with or without DEX
treatment, as described above. Slide-mounted cells were used
for immunostaining of RhoGDI by means of an HRP-DAB
Cell and Tissue Staining Kit (Maixin-Bio, Fuzhou, China)
according to the manufacturer’s instructions. Briefly, TMCs
were fixed in ice-cold acetone for 20 min and cell membranes
were permeabilized with 0.1% Triton X-100, followed by
quenching of the endogenous peroxidase activity with 3%
H2O2  and  blocking  non-specific  binding  with  goat  serum
albumin. Then, cells were incubated with antibodies against
RhoGDI (#2564; Cell Signaling Technology, Danvers, MA)
at 4 °C, overnight. Cells were then incubated with secondary
goat antibodies, and color development was done with DAB
reagents. A negative control was run, in which the cells were
incubated in PBS without the addition of primary antibodies.
Protein  extraction:  Pooled  TMT  was  thoroughly  cut  into
small pieces with a scissor. Then an aliquots-of-lysis buffer
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214(8  mol/l  urea,  4%  CHAPS,  2%  Pharmalyte  3–10;  GE
Healthcare, Ltd., NJ) was added to the samples, followed by
homogenization and sonication on ice. The soluble protein
was obtained by centrifugation (at 12,000× g for 30 min at
4 °C). For cultured cells, collection was performed by rinsing
with PBS, removal from the flask with a rubber policeman,
and pelleting at 500× g centrifugation. After adding an aliquot
lysis buffer, cell pellets were sonicated. Insoluble materials
were removed by centrifugation (at 12,000× g for 30 min
4 °C). The soluble protein portion was quantified by BCA
assay using a protein assay kit (Bio-Rad, Hercules, CA) and
stored at −80 °C until the next analyses.
Two-dimensional gel electrophoresis: Two-dimensional gel
electrophoresis was performed using instruments, kits, and the
2-DE  protocol  from  GE  Healthcare  (GE  Healthcare  Bio-
Sciences  AB,  Uppsala,  Sweden),  and  according  to  our
previously  reported  protocols  [40],  unless  otherwise
specified.  Briefly,  the  extracted  protein  solution  was
precipitated  with  a  2-D  clean-up  kit.  The  pellets  were
dissolved  in  rehydration  solution  to  a  certain  volume,
according to the size of the immobilized pH gradient (IPG)
strips, and centrifuged at 15,000× g for 10 min to remove
insoluble materials. The supernatant was used as the loading
sample on the IPG strips.
First-dimensional  isoelectric  focusing  (IEF)  was
performed using the Ettan IPGphor II unit. IPG strips (18 cm,
pH 3–10, linear gradient) were loaded with protein samples
and  rehydrated  overnight.  Isoelectric  focusing  was  run  at
15 °C, totally focused over 8 kVh. First dimension strips were
subjected to the standard reduction and alkylation steps before
second-dimension electrophoresis, as follows. The strips were
soaked for 15 min in 50 mM Tris-HCl solution (pH 8.8)
containing 6 M urea, 30% glycerol, 2% SDS, 2% DTT, and
0.001% bromophenol (w/v). They were then soaked for an
additional 15 min in the same solution, except that 2.5%
iodoacetamide was substituted for the 2% DTT.
The second-dimensional electrophoresis (SDS–PAGE)
was conducted on 10% polyacrylamide gels (PROTEAN® II
xi  Cell;  Bio-Rad)  with  protein  molecular  weight  markers
(Takara  Biotech  Co.  Ltd.,  Dalian,  China).  At  the  end  of
electrophoresis,  gels  were  stained  with  hot  Coomassie
brilliant blue R-350 [41].
After  destaining,  gels  were  scanned  using  an
ImageScanner  II  and  analyzed  by  Melanie  software  (GE
Healthcare). Protein spots were first outlined automatically,
and many were further outlined manually, and quantified. The
measured molecular weight (Mr) and isoelectric point (pI)
values of each protein spot were calculated according to the
method introduced by Westermeier and Naven [42].
Mass  spectral  analysis  and  protein  identification:  MS
analysis and protein identification were performed as reported
previously [40,43]. Following imaging analysis, protein spots
on the large gel run with TMT protein were selected for
identification. Spots with relatively higher intensities on 2-DE
gels were excised, dried, digested with trypsin (sequencing
grade;  Promega,  WI),  and  mechanically  spotted  onto  MS
plates  by  an  Ettan  Spot  Handling  Workstation  (GE
Healthcare). The molecular masses of peptides were measured
by MALDI-TOF-MS using an Ettan MALDI-TOF Pro mass
spectrometer (GE Healthcare). On the basis of peptide-mass
matching, peptide peaks obtained from mass mapping were
identified  using  the  NCBInr  database.  All  spots  were
examined  for  methionine  oxidation,  for  iodoacetamide
modification, and, with no-limitation, for pI. The confidence
of identification was indicated by the number of matching
peptides,  and  the  percent  of  the  amino  acid-sequence
coverage. Proteins were accepted on the basis of four or more
peptides having matched [43].
Cluster  analysis  of  trabecular  meshwork  proteins:  The
categories of identified proteins were analyzed by inputting
their  accession  codes  into  a  bioinformatic  databse,  which
automatically classifies genes based on gene ontology (GO)
terms. Before GO-based binning, any identified protein with
a GI code was recoded according to gene/RefSeq accession
numbers, using the websites UniProt, NCBI, and BLAST.
Western blotting analysis: Western blotting was conducted
according to specifications of the antibody manufacturer and
our previous report [40]. Briefly, aliquots of lysates (30 μg of
protein equivalent) were subjected to 10% SDS–PAGE under
reducing conditions, then blotted onto a PVDF membrane.
Antibodies against RhoGDI (#2564) and RhoA (#2117), and
a Phototope-HRP western blot kit (all from Cell Signaling
Technology)  were  used  for  western  blotting  assay.
Densitometric  analysis  was  performed  to  measure  the
intensity of the RhoGDI and RhoA bands with the use of the
molecular  imaging  software  in  the  Kodak  Image  Station
4000MM  (Kodak,  Rochester,  NY).  Each  experiment  was
repeated three times.
RESULTS AND DISCUSSION
Protein  expression  pattern  on  two-dimensional
electrophoresis  gels:  To  date,  2-DE  protein-expression,
combined gel-spot identification for human TMT has not yet
been conducted because of difficulties in obtaining enough
proteins from limited tissue samples, although the proteome
of TMCs has been extensively studied [29,33,44]. In this
study, the 2-DE gel pattern of human TM tissue and a human
TMC line was obtained. We first compared the 2-DE protein
patterns of human normal TMT to that of TMCs. Figure 1
shows that the protein spot distribution of TMCs is somewhat
different from that of the TMT on the 2-DE gel. However, the
average number of protein spots on TMT gels (877) was
similar to that on TMC gels (963). In the current study, we
used 2-DE (18 cm×20 cm, gel size) to separate the soluble
protein of human TMT, and only observed 877 protein spots
on the gels stained with Coomassie brilliant blue R-350. It
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215should  be  kept  in  mind  that  the  limitations  of  2-DE
proteomics, that is, missing high molecular-weight proteins,
proteins outside the pI range of the isoelectric focusing gel,
many  insoluble  proteins,  and  low-abundance  proteins,
account for many of the TM proteins not found on the gels.
The distribution of the protein spots detected in the gel
was determined by means of their pI and molecular mass
(Appendix 1). According to the data measured on each gel,
more than 67% of the TMT protein spots had a pI between 5
and 8, and approximately 89% of the identified spots had
masses between 20 kDa and 100 kDa. Among TMC protein
spots, 74% had a pI between 5 and 8, and 91% had masses
between  20  and  100  kDa.  In  Appendix  1,  there  were
discrepancies  between  the  calculated  pI  and  Mr  values,
compared to the measured pI and Mr values for many of the
identified spots. This is because we obtained the measured pI
by pH gradient graphs and the measured Mr values by co-
running molecular weight standard proteins [42]. The data
accuracy  was  limited  by  reference  markers  and  by  the
accuracy of measurement on the gels. The theoretical pI and
Mr values were calculated from the amino acid sequence of a
protein in the database, with fewer effects concerning the post-
translation modification and the molecular stereostructure.
Therefore, we could see that the many identified proteins in
Appendix 1 had different measured and theoretical pI or Mr.
However, the mapping data we present here could prove to be
a  useful  reference  for  future  studies  on  differentiating
expressed  proteins  in  the  TM  from  various  glaucoma
disorders.
Few  early  works  used  2-DE  to  display  the  protein
expression of human TM. Steely et al. [45] reported a human
TM protein pattern obtained from 2-DE gels (16×21 cm) using
radio-labeled  samples  visualized  by  X-ray  film  exposure.
More than 400 spots were observed by this technique, but no
further identification was pursued. In an earlier report, Russell
and colleagues [34] compared the age-related differences of
human TM protein maps on 2-DE gels. Their studies obtained
approximately 160 spots from TM proteins of donors aged 9
to 91 years old. Clearly, our technique resulted in more protein
spots being detected upon 2-DE gel separation. Additionally,
2-DE  has  been  previously  used  to  display  the  protein
expression of TMCs with or without DEX treatment [33,46].
In the present study, we compared the 2-DE pattern of human
TMT and a TMC line. We reported the pattern for 877 proteins
from human normal TMT, 235 of which were identified and
localized on a 2-DE gel. Since Steely et al. [33] have displayed
a 2-DE protein pattern for the GTM3 cell line, and effectively
identified  87  primary  proteins  and  93  variants  of  these
proteins, we did not pursue detailed protein identification for
those spots detected from our TMC analysis.
Proteins identified from human trabecular meshwork: The
protein spots separated on the gel (Figure 2) were identified.
Figure 1. Protein expression map of human trabecular meshwork by two-dimensional gel electrophoreses. Human trabecular meshwork tissue
(TMT) and cell (TMC) lysates (approximately 1 mg protein) were applied to 2-DE gel (18 cm strips) that was visualized by Coomassie blue
staining.
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216A  total  of  444  visible  spots  from  the  2-DE  gel  were
mechanically treated by the spot-handling workstation; 235
of these were subsequently identified by MALDI-TOF-MS.
Among the 235 identified spots, 72 were determined to be
identical by protein accession number. Therefore, Appendix
1 is only composed of 163 proteins with varying parameters,
including protein name and accession number, theoretical and
measured Mr and pI values, matched the peptides and amino
acid sequence coverage. The spot number marked on the gel
(Figure 2) for localizing a particular protein has also been
indicated in Appendix 1. It was surprising to find that about
one-third of the protein spots (72/235) belonged to isomers or
were products of post-translational modifications. The spots
representing variants of the same protein on the 2-DE of TM
has previously been reported for the GTM3 cell proteome
[33]. These dynamic proteins may serve as focused targets for
future studies, to determine their functional significance in
TM and glaucoma.
Several of the proteins we identified in TM have been
reported  to  be  associated  with  glaucoma.  For  example,
myocilin was initially identified as a 55 kDa protein secreted
into the media of TM cultures and induced by glucocorticoid
[12,47,48]. Myocilin affects the flexibility and resilience of
TM,  which,  if  disrupted,  may  lead  to  alteration(s)  in  the
aqueous outflow [38]. In the current study of normal human
TM, myocilin was identified in two individual spots, with
different  molecular  weights  on  2-DE  (spots  147  and  154
shared the same protein code, Figure 2,Appendix 1), which
suggests the possibility of a post-translational modification.
In  addition,  Steely  et  al.  [33]  suggested  that  calreticulin,
located on the acidic side at 62 kDa (spot 26), might be
modified  by  glycosylation,  since  its  expected  mass  is
48.1 kDa. Glycosylation may influence both the calcium-
signaling role and chaperonin activity of calreticulin in TMCs.
Other  studies  have  demonstrated  that  a  mutation  of
cytochrome P450 (spot 54) could result in primary congenital
glaucoma  in  some  patients  [17,49].  Expression  of  the
angiopoietin-like factor CTD6, one of the 15 most abundant
types of cDNA in TM [50], was believed to stimulate the
deposition of specific ECM in the cornea [51]. In our present
study, there were at least four spots (spot 63, 170, 181, and
182) identified as angiopoietins, which suggested this protein
may play a key role in normal TM, and possibly in glaucoma.
Meanwhile, several identified proteins in this study belonged
to  cytoskeletal  protein  families  or  extracellular  matrix
proteins, such as vimentin, lamin, actin, and annexin. These
proteins were also the major components involved in TMCs
in response to DEX or transforming growth factor β (TGF-β)
treatment [7-19,29], and regulated by Rho GTPase [4]. The
above-mentioned proteins are expressed in normal TMT, and
they have also been reported to be changed in studies on TMCs
in vitro or in vivo. We anticipate a similar scenario for other
yet-uncharacterized  proteins  that  merit  future  study.  For
example, RhoGDI (spot 225) was downregulated in our DEX-
Figure 2. Localization of identified proteins on two-dimension electrophoresis (2-DE) gel. Two-hundred-and-thirty-five protein spots from
the 2-DE gel of human TMT are localized on two images, where spots 1–117 are located on the left and 118–235 on the right. Protein spots
were excised and identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The spot
numbers indicated on the gel images are listed in Appendix 1.
Molecular Vision 2010; 16:213-223 <http://www.molvis.org/molvis/v16/a27> © 2010 Molecular Vision
217treated TMCs, which will be discussed in later sections of this
paper.
The identified proteins were clustered according to gene
ontology (Table 1). Based on GO biological terms, the major
categories of identified proteins were metabolic process, cell
adhesion,  anti-apoptosis,  cell  motility,  carbohydrate
metabolic  process,  signal  transduction,  and  regulation  of
transcription. In Table 1, we also presented the categories of
identified proteins from human TMT from Bhattacharya et al.
[31] and from TMCs from Steely et al. [33]. Bhattacharya et
al. [31] identified 316 proteins from human TMT by SDS–
PAGE and liquid chromatography (LC) tandem MS. Steely et
al. [33] revealed the 2-DE based proteome of TMCs and
identified fewer spots compared to our study. Generally, the
major categories of identified proteins in our study were very
similar to those of Bhattacharya et al. [31]. However, several
kinds  of  proteins  were  absent  or  less  abundant  in  the
Bhattacharya et al. [31] TMT proteome. It is possible that this
discrepancy is due to the the two studies’ different protein-
separation techniques. We took the visible spots from 2-DE
gels for the subsequent tryptic digestion and MALDI-TOF-
MS analysis. In Bhattacharya et al., SDS–PAGE combined
LC/MS/MS might have been able to identify some proteins
present only in trace amounts.
Dexmethasone effects on trabecular meshwork cells in vitro:
We next used DEX-treated TMCs, an approach widely used
to study the mechanism of glaucoma, to search for differential
expression  patterns  of  proteins.  It  has  been  reported  that
treating  cultured  TMCs  for  weeks  with  DEX  causes  a
significant increase in average TMC size and significantly
increased nuclear size [8,9]. In the present study, we could not
detect  significant  differences  between  normal  and  DEX-
treated TMCs using phase-contrast microscopy throughout
the three-day study period. However, we did observe that the
proliferation  rate  of  TMCs  was  inhibited  by  10−5–10−7  M
DEX,  as  evidenced  by  MTT  analysis  (Figure  3).  The
TABLE 1. CATEGORY LISTS OF BIOLOGIC PROCESSES OF TM PROTEINS IN HUMAN TRABECULAR MESHWORK.
Present study* TM tissue$ TM cell#
Categories Protein number%Protein number%Protein number %
metabolic process 19 13.4 19 6.8 4 5.6
cell adhesion 11 7.7 13 4.7    
anti-apoptosis 11 7.7 11 3.9 6 8.5
cell motility 11 7.7 10 3.6 6 8.5
carbohydrate metabolic process 10 7.0 6 2.2    
signal transduction 9 6.3 21 7.5 3 4.2
regulation of transcription, DNA-dependent 8 5.6     6 8.5
biological_process 8 5.6 13 4.7    
nervous system development 8 5.6 5 1.8    
glycolysis 8 5.6 14 5.0 6 8.5
transcription 7 4.9     7 9.9
cell cycle 7 4.9 4 1.4 4 5.6
cell proliferation 7 4.9 9 3.2 3 4.2
visual perception 7 4.9 13 4.7    
multicellular organismal development 6 4.2        
electron transport 6 4.2 7 2.5    
ion transport 6 4.2 9 3.2    
response to stimulus 6 4.2 6 2.2    
response to oxidative stress 6 4.2 5 1.8 2 2.8
protein folding 6 4.2 8 2.9 12 16.9
protein targeting 6 4.2        
protein amino acid phosphorylation 5 3.5 6 2.2    
muscle contraction 5 3.5        
transport 4 2.8 12 4.3 4 5.6
G-protein coupled receptor protein signaling
pathway
4 2.8 5 1.8    
proteolysis 4 2.8 10 3.6    
cell division 4 2.8     2 2.8
cell-cell signaling 4 2.8 5 1.8    
lipid metabolic process 4 2.8 10 3.6 3 4.2
The asterisk indicates the percentage was calculated on 142 proteins that matched in the cluster searching upon GO database.
The  dollar sign indicates data from Bhattacharya et al. [31] with 279 and the sharp (hash mark) indicated from Steely et al.
[33] with 71 proteins that matched in the database.
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218inhibition appeared after 48 h and 72 h of DEX treatment.
Generally, 10−7 M DEX has been widely used in previous
studies [9,13,37]. Since short-term cultured TMCs were used
in the current study, we used three concentrations, including
two higher concentrations (10−6 and 10−5 M) of DEX, to see
the more obvious effects on the cell proliferation and protein
expression  of  TMCs.  A  stronger  inhibition  of  TMC
proliferation occurred at the highest DEX level. The effect of
DEX occurred with the highest inhibition of cell proliferation
at 10−5 M at 72 h of treatment.
RhoGDI  downregulated  in  dexamethasone-treated
trabecular meshwork cells: We used proteomic analysis to
characterize the differentially expressed proteins in cultured
TMCs. We found that RhoGDI was the changed protein spot,
as evidenced by immunoassays (Figure 4), which revealed
that, in DEX-treated TMCs, RhoGDI expression decreased in
a  dose-dependent  manner.  By  comparing  the  2-DE  gel
patterns of the lysates from TMC lines treated with or without
DEX,  the  RhoGDI  spot  exhibited  lower-intensity  staining
(Figure 4A). By western blot analysis, the expression of the
RhoGDI molecule appeared to be reduced in 24 h DEX-
Figure  3.  Temporal  changes  in  the  absorbance  over  the
dexamethasone  (DEX)  treatment.  Trabecular  meshwork  cells
cultured in 0, 0.1, 1, and 10 μm of DEX were terminated at the
indicated time, then stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium  bromide  (MTT)  to  obtain  the  absorbance
measurement. The data represented the results of three independent
experiments.  Errors  on  the  points  indicate  standard  deviation.
Compared  to  control  group,  there  were  significant  decreases  of
absorbance in 10 μm DEX-treated cells at 24 h (p<0.05) and in all
three DEX groups at 48 h and 72 h (p<0.01).
In summary, the current study provides 2-DE gel patterns
of human TMT and a TMC line.  We  detected  more  than 850
spots  for  both  lysates,  and  235  spots  were  successfully
identified using 2-DE gel analysis of human normal TM.
These data will establish the foundation for future studies into
the comprehensive protein expression patterns and effects in
normal  and  glaucomatous  TM.  Furthermore,  by  using
proteomic methods combined with immunoassays, we have
provided evidence of decreasing RhoGDI expression in DEX-
treated TMCs. There were distinct effects of DEX on the
expression of RhoGDI and RhoA in TMCs. These results may
prove  useful  to  begin  a  focused  study  of  glaucoma
pathogenesis.
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treated cells (Figure 4B). Higher levels of DEX displayed a
general pattern of more obvious decreases, as compared to
10−7 M of DEX. The decrease of RhoGDI expression was also
evidenced  by  immunocytochemical  staining  (Figure  4C).
10−6 M DEX reduced the RhoGDI staining in TM cytoplasm,
compared to that in mock and control cells. Furthermore,
RhoA, a target of RhoGDI, is known to function in TM as a
cytoskeleton and ECM regulator. Therefore, RhoA inhibition
may be the possible mechanism leading to TMC or tissue
damage [4,23,52]. In the present study, we assayed the RhoA
expression in our cultured cells. The results revealed that the
expression of RhoA was opposite to that detected for RhoGDI
by  western  blot  assay  (Figure  4D-F).  It  was  also  a  dose
dependent effect, with higher expression corresponding to
higher  DEX  levels.  There  were  a  variety  of  reports  that
showed  that  RhoA  increased  the  levels  of  promoted
production of fibronectin, tenascin C, laminin, alpha-smooth
muscle  actin,  collagen  IV,  laminin,  and  phosphorylated
myosin light chains, as well as increased the expression of
genes  encoding  ECM  proteins,  cytokines,  integrins,
cytoskeletal proteins, and signaling proteins in TMCs. The
protein  kinase  inhibitors,  including  Rho  kinase  inhibitors,
could  alter  TMC  shape  and  adherence,  disrupt  the  actin
bundles, and increase aqueous outflow, thereby lowering IOP
[4,53-56]. Meanwhile, RhoGDI forms a complex with the
GDP-bound form of the Rho family proteins (e.g., RhoA), to
regulate  the  activation  state  of  RhoGTPase  [26].  Thus,
RhoGDI,  by  repressing  RhoA  activity,  may  regulate
organization of the actin cytoskeleton and cell–cell adhesions
in  TMCs.  In  the  present  study,  our  results  revealed  that
opposite  effects  of  DEX  treatment  on  the  expression  of
RhoGDI and RhoA in TMCs, suggesting that DEX increases
the  RhoA  activity,  at  least  in  part,  by  antagonizing  the
RhoGDI function. However, the detailed relationships and
interactions of RhoGDI-related proteins, in glaucomatous TM
in particular, remain unclear.ACKNOWLEDGMENTS
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